Lunit Inc. 328130

Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that its AI-powered mammography solution, Lunit INSIGHT MMG, will be implemented as an independent second reader across the entire Stockholm Region in Sweden, building on years of successful clinical validation and real-world use at Capio Saint Göran Hospital.

10x Genomics has delivered an unusually strong share price run over the past year, which puts a spotlight on whether the current valuation lines up with its sales base. With the stock now well above where it traded in prior years, investors are increasingly asking how much of the business story is already reflected in the price. Over the last 12 months, the stock has returned roughly 4.9x, which raises the question of how much future sales progress is already being assumed in the current...

Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the 2026 World Conference on Lung Cancer (WCLC 2026), to be held in Seoul, South Korea, from September 12 to 15.

CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced the launch of its Global Digital Pathology and AI Consortium, a curated ecosystem of leading digital pathology, artificial intelligence and precision diagnostics innovators designed to help biopharma sponsors accelerate biomarker discovery, patient stratification, clinical trial execution and companion diagnostic strategy across oncology, autoimmune, Alzheimer's disease and other indications as needed.

Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, presented six studies at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17 to 22 in San Diego, California.

At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI.

Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta, a leading global contract research organization (CRO) laboratory to the biopharmaceutical industry, today announced a strategic partnership to accelerate adoption of AI-enabled digital pathology workflows across translational research, clinical trials and companion diagnostic (CDx) programs.